Madrigal Pharmaceuticals (MDGL) Earning Somewhat Positive News Coverage, Analysis Shows
News headlines about Madrigal Pharmaceuticals (NASDAQ:MDGL) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.6257932802161 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Separately, ValuEngine raised Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 19th.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Thursday, May 11th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.37.
COPYRIGHT VIOLATION WARNING: “Madrigal Pharmaceuticals (MDGL) Earning Somewhat Positive News Coverage, Analysis Shows” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/07/madrigal-pharmaceuticals-mdgl-receiving-somewhat-positive-media-coverage-study-finds-updated.html.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Stock Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.